LENZ Therapeutics, Inc.
LENZ
$7.34
$0.050.69%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 304.57% | 323.57% | 324.95% | 72.76% | 100.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 171.90% | 163.06% | 142.46% | 52.29% | 5.24% |
| Operating Income | -160.68% | -152.63% | -45.90% | -17.45% | -5.24% |
| Income Before Tax | -183.80% | -183.72% | -63.49% | -40.55% | 12.19% |
| Income Tax Expenses | -- | 100.00% | -- | -- | -- |
| Earnings from Continuing Operations | -183.80% | -183.72% | -63.49% | -45.43% | 12.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -183.80% | -183.72% | -63.49% | -45.43% | 12.19% |
| EBIT | -160.68% | -152.63% | -45.90% | -17.45% | -5.24% |
| EBITDA | -160.57% | -152.34% | -45.05% | -17.47% | -5.05% |
| EPS Basic | -149.16% | -151.04% | -55.65% | -32.64% | 84.95% |
| Normalized Basic EPS | -149.17% | -151.04% | -55.62% | -13.76% | 84.95% |
| EPS Diluted | -149.16% | -151.04% | -55.65% | -32.64% | 84.95% |
| Normalized Diluted EPS | -149.17% | -151.04% | -55.62% | -13.76% | 84.95% |
| Average Basic Shares Outstanding | 13.90% | 13.02% | 5.04% | 9.65% | 483.48% |
| Average Diluted Shares Outstanding | 13.90% | 13.02% | 5.04% | 9.65% | 483.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |